Related Experiment Video
Updated: Jan 10, 2026

Closure of a Patent Foramen Ovale PFO: An Intervention Sequence
Published on: December 23, 2022
Atrial septal defect closure as second-line therapy in refractory heart failure: a successful case report in a
Sofiane Mimoun1, Alban-Elouen Baruteau1,2,3,4, Bruno Lefort5,6
1Nantes Université, CHU Nantes, Department of Pediatric Cardiology and Pediatric Cardiac Surgery, FHU PRECICARE, 7 quai Moncousu, 44093 Nantes cedex 01, Nantes F-44000, France.
Insights
Atrial septal defect (ASD) closure can be a life-saving option for patients with impaired left ventricular compliance. Percutaneous closure using a fenestrated device successfully treated a child with heart failure due to ASD and myocarditis.
Area of Science:
- Cardiology
- Pediatrics
- Congenital Heart Disease
Background:
- Atrial septal defect (ASD) is a common congenital heart defect.
- ASD typically remains asymptomatic in childhood but can cause heart failure when left ventricular (LV) compliance is impaired.
Background:
Atrial septal defect (ASD) is a common congenital heart defect that remains mainly asymptomatic in childhood. However, when left ventricular (LV) compliance is impaired, as in myocarditis or cardiomyopathy, ASD may lead to severe heart failure due to increased left-to-right shunting and a reduced systemic cardiac output.
Case Summary:
We report the case of a 6-year-old boy with CDG-PGM1 and a large ASD who developed acute refractory heart failure, likely triggered by Parvovirus B19 myocarditis. Despite optimal medical therapy, including immunoglobulins, inotropes, and heart failure medication, he remained dependent on pharmacological support. He was deemed ineligible for heart transplantation due to his underlying metabolic condition; therefore an ASD closure was questioned as a last therapeutic option. A balloon occlusion test showed a mild increase in LV end-diastolic pressure, allowing percutaneous closure using a hand-made fenestrated device. The procedure was successful, leading to rapid weaning from inotropes and full clinical recovery. At 6-month follow-up, LV function was normalized, and the patient was asymptomatic.
Conclusion:
In selected patients with impaired LV compliance, ASD closure may offer a life-saving therapeutic option. Haemodynamic evaluation with balloon occlusion testing is essential to evaluate closure feasibility and determine the potential need of using a fenestrated device.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Mitral Stenosis III: Medical Management
Cardiomyopathy IV: Restrictive Cardiomyopathy
Mitral Regurgitation III: Medical Management

